OTCQX:MRVFF - Post by User
Post by
PDMitchellon Feb 16, 2013 5:31pm
336 Views
Post# 21000836
Pennsaid safety NOT questioned
Pennsaid safety NOT questioned As Doctordoctor pointed out earlier this week
"The reference is MecGettigan P. & Henry D. Cardiovascular Risk with Non-Steriodal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med. 2011. 8 (9): e1001098. Their search criteria yielded 30 case control studies and 21 cohort studies. You can access it from PubMed.
Using a weighted anayses from 31 studies, the use of diclofenac was associated with increased cardiovascular risks. This was expressed as a pooled odds ratio of 1.4 (1.27 - 1.55). However, 15 of the 31 studies did not show an increased risk (confidence interval crossing 1). Secondly, the heaviest weighed studies (>4%) all showed increased risk. This may introduce an element of study selection bias.
Regardless, the publication is not very recent. It will very unlikely have a role in the upcoming FDA decision. Furthermore, topical application is very different from enteral or intravenous formulations. There are several medications (ie Elidel, Protopic, diprolene) that are routinely available in the topical formulation, but are very closely monitored when their enteral/intervenous equivalents are administered.
Moreover even the athors, or at least your article, admit that "For those who have a low risk of heart attacks, diclofenac does not increase the heart risks to any great degree."